BioHealth Innovation, Inc. (BHI), a public-private partnership and innovation intermediary is seeking an energetic and motivated life science professional for the role of an Entrepreneur-In-Residence (EIR) with product development experience and subject matter expertise in the fields of neurology and neuroscience. The EIR will reside within the National Institutes of Health (NIH) and will also support intramural and extramural initiatives on an as needed basis.
The EIR program was established at BioHealth Innovation to:
Retain and bring entrepreneurial talent to the Maryland ecosystem
Connect resources including institutions, technology assets, people and capital within Maryland that include federal institutions, labs, academic institutions, small businesses, disease foundations and the investor community
Build/support sustainable life science startups that will add value within the healthcare system and also build upon the existing infrastructure
The EIR will work with BHI leadership to ensure that the activities and outcomes are aligned with BHIs strategic focus.
GlaxoSmithKline (GSK) has taken control of Swiss company GlycoVaxyn in a $190m deal that bolsters its early vaccines pipeline.
GSK already owned a stake in GlycoVaxyn and had been working with the company since 2012 on the development of conjugate vaccines for bacterial infections.
Sucampo Pharmaceuticals, a global biopharmaceutical company, announced that Sucampo and R-Tech Ueno, Ltd. (RTU), have entered into a stipulation and licence agreement with Par Pharmaceutical, Inc. (Par). The agreement states that in limited circumstances, Sucampo or RTU would grant Par a licence for a generic version of the RESCULA (unoprostone isopropyl ophthalmic solution) 0.15 per cent product approved for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension prior to the latest expiration date of the patents, which is July 2021. Par had previously submitted an Abbreviated New Drug Application to the US Food and Drug Administration requesting approval to market, sell, and use a generic version of RESCULA.
Swiss cancer drugs giant Roche (ROG: SIX) has acquired Signature Diagnostics, a privately-held company based in Potsdam, Germany. Financial terms of the transaction, which is the fifth deal in the past year aimed at building Roche’s molecular diagnostics business, were not disclosed.
The Lifetime Achievement award is given to individuals who have gone above and beyond over the course of their career to serve our community. This year, we have expanded our award categories and are proud to recognize three outstanding individuals in the fields of technology, life science, and education.
Our past recipients include Clifford M. Kendall, Chairman and CEO (Retired) of Computer Data Systems, Inc., Dr. Freeman A. Hrabowski III, President of the University of Maryland, Baltimore County (UMBC), Dr. James Barrett of New Enterprise Associates, and Ted Leonsis, Founder, Majority Owner, Chairman and Chief Executive Officer, Monumental Sports & Entertainment.
Johns Hopkins University President Ronald Daniels has seen plenty of innovation at the world-renowned research institution he leads. In opening a second incubator in East Baltimore, university officials believe they can get another benefit from the innovation.
“It’s happened before at Hopkins and it’ll happen again,” Daniels said of inventions that come out of the university. “But this time, we’re going to make some money on it.”
This is a Request for Proposal to lease the Good Manufacturing Practices (GMP) facility located at the Institute for Bioscience and Biotechnology Research (IBBR), on the University System of Maryland’s Shady Grove campus at 9600 Gudelsky Drive, Rockville, MD 20850.
IBBR is a University System of Maryland joint research enterprise between the University of Maryland College Park, The University of Maryland Baltimore and the National Institute of Standards and Technology. IBBR’s Vision and Mission are as follows:
Maryland could establish a $5 million fund to put toward tax credits for individuals and firms who invest in startup companies.
Startup and investor advocates, including the Greater Baltimore Committee, have said they will push for the state to create a new tax credit specifically for angel investors who give money to companies at their earliest stages, when they often struggle to bring in needed cash. A bill introduced by Baltimore City Democrat Sen. Catherine Pugh earlier this month details how the tax credit would work and who could qualify as an investor and startup recipient.
The EY Entrepreneur Of The Year™ Award has become the mark of world-class individuals leading world-class companies. We invite you to be part of this exciting program. About the Entrepreneur Of The Year Program
EY Entrepreneur Of The Year honors entrepreneurs whose ingenuity, hard work and perseverance have created and sustained successful, growing business ventures. The program is celebrating its 29th year and has expanded to more than 140 cities and 50 countries around the world. EY forms a group of individuals from the business community to participate as the independent panel of judges for the program. This panel is made up of past award winners and C-suite leadership of high-growth entrepreneurial organizations. It also includes influential business leaders from the venture capital and private equity communities.
Notice of Pre-Application Webinar for PA-14-015 Ruth L. Kirschstein National Research Service Award (NRSA) (Parent T32) Related to the Creation of New NHGRI Postdoctoral Training Programs in Genomic Medicine Res
(NOT-HG-15-014) National Human Genome Research Institute
Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.
In today’s world, the average adult between the ages of 65 and 69 takes almost 14 prescriptions per year, and those aged 80-84 take 18 prescriptions. With the safety information for each medication constantly changing, it can be difficult for consumers to be informed about their medications.
Four University System of Maryland schools rank among the top 100 public universities in the country, according to a new statistical analysis by The Business Journals.
University of Maryland, College Park, scored highest among Maryland’s public universities, coming in at No. 8 out of 484 schools nationwide. St. Mary’s College of Maryland; University of Maryland, Baltimore County; and Towson University also ranked in the top 100. Salisbury University ranked 107th.
While regulation of diagnostic tests by the Food and Drug Administration (FDA) may not directly impact the biobanking industry, it does have an impact on the development of new therapies, particularly personalized medicine, and all of us have a stake in the future of personalized medicine.
National Institutes of Health director Francis Collins kicked off a two-day meeting in Bethesda, MD, this morning to discuss how to turn President Obama’s call for a national health research database into reality. The database, which NIH officials are calling the National Research Cohort, is one of two main thrusts of the administration’s precision medicine initiative.
Fourteen years ago, during the darkest moments of the “stem-cell wars” pitting American scientists against the White House of George W. Bush, one group of advocates could be counted on to urge research using cells from human embryos: parents of children with type 1 diabetes. Motivated by scientists who told them these cells would lead to amazing cures, they spent millions on TV ads, lobbying, and countless phone calls to Congress.
How are venture capital dollars are actually disseminated? Into early stage companies? Late? What fields get the most investment – cancer?
Bruce Booth of Atlas Ventures blogged about this today on his Life Sci VC site about this topic, highlighted in a new whitepaper from BIO. Here are the highlights:
District regulators approved the city’s first equity crowdfunding campaign last week. It was also the only application they’ve received to date.
The Department of Insurance, Securities and Banking approved equity crowdfunding rules last October as a way for the city’s entrepreneurs to raise small sums of money from city residents in exchange for a piece of their business.
Google is altering the way it displays search results. Over the next few days, Google Search will begin to dish out health bits of facts with search news. This is Google’s new attempt at health news, in fact, this could be a way to reimagine the now defunct Google Health.
This is not a first for Google. Its feet are firmly planted in the health space, having previously launched feature where people can connect to a doctor via video and its .
Crowdfunding is a hot idea in small biopharma, but a lot of people don’t quite know what to make of it. I’ve written about some academic examples of it, and I think that’s a good use of the idea. People can donate in the expectation that they’re helping along a research project, not because they’re looking for a big return on their money.
The NFL, GE, and Under Armour officials announced that they have joined with the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) to launch Head Health Challenge III, an open innovation competition to advance materials that better absorb or dissipate energy. These new materials could improve the performance of protective equipment for athletes, military personnel and those in dangerous occupations.
Partners HealthCare is proud to announce the 2015 World Medical Innovation Forum, an annual gathering in Boston of more than 1,000 top innovation decision makers. The inaugural event will focus on neurosciences and be held on April 27-29, 2015. The goals of this three-day event are to identify today’s leading neuroscience innovations, address unmet needs, and discuss the critical issues affecting technology development and implementation in this new, evolving era of value-based care.
The recent February issue of Health Affairs, which features a series of articles on innovation, provides us with an opportunity to examine the state of America’s innovation ecosystem for medical technology. This ecosystem has produced a myriad of medical advances, ranging from advanced imaging to molecular diagnostics, minimally invasive surgical tools, and incredibly sophisticated implants. These technologies have shortened hospital stays, reduced the economic burden of disease, and saved and improved millions of lives.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
